These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2446483)

  • 1. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
    Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
    Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Testosterone, FSH and LH level in the serum of patients with prostatic neoplasms, treated with female hormones].
    Weidner W; Krause W; Pust R; Engstfeld J; Rothauge CF
    Helv Chir Acta; 1978 Jul; 45(3):287-90. PubMed ID: 701064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H; Usami M; Kotake T; Koiso K; Aso Y
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of CMA in the treatment of prostatic cancer].
    Fukuoka H; Goto A; Murai T; Satomi Y; Moriyama M; Senga Y; Shirai K; Nakao H
    Hinyokika Kiyo; 1986 Dec; 32(12):1821-30. PubMed ID: 2435131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
    Aso Y; Akaza H; Koiso K; Kameyama S; Koyanagi T; Kawai T; Kumamoto Y; Tazaki H; Funyu T; Oshima H
    Hinyokika Kiyo; 1993 Apr; 39(4):391-403. PubMed ID: 8503339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
    Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
    Maleeva A; Tsvetkov M; Kekhaĭova M
    Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [H2 histamine antagonists and the hypothalamo-hypophyseal-gonadal axis: effect of short-term treatment on serum levels of prolactin, FSH, LH and testosterone in male ulcer patients].
    Biagi P; Galli M; Brettoni A; Rizzo AA; Massafra C
    Quad Sclavo Diagn; 1983 Sep; 19(3):313-21. PubMed ID: 6146158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
    Stahl F; Schnorr D; Rohde W; Dörner G
    Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.